Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2022), Nat Med
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Journal article
Shaw RH. et al, (2022), Lancet Respir Med
Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.
Journal article
Hodgson SH. et al, (2022), Clin Transl Sci, 15, 524 - 534
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2022), Lancet, 399, 36 - 49
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.
Journal article
Dejnirattisai W. et al, (2021), Lancet
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Journal article
Clemens SAC. et al, (2021), Nature Communications, 12
Transmission of community- and hospital-acquired SARS-CoV-2 in hospital settings in the UK: A cohort study.
Journal article
Mo Y. et al, (2021), PLoS Med, 18
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
EWER K. et al, (2021), The Lancet
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Journal article
Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046
SARS-CoV-2 within-host diversity and transmission
Journal article
Lythgoe KA. et al, (2021), Science (New York, N.Y.), 372
SARS-CoV-2 within-host diversity and transmission.
Journal article
Lythgoe KA. et al, (2021), Science, 372
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
Assessing COVID-19 cohorting strategies in a UK district general hospital during the first wave of COVID-19.
Journal article
Davies T. et al, (2021), Clin Med (Lond), 21, 40 - 41
Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.
Journal article
Volz E. et al, (2021), Cell, 184, 64 - 75.e11
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.
Journal article
Lumley SF. et al, (2020), The New England journal of medicine
The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers
Journal article
Lumley SF. et al, (2020), Clinical Infectious Diseases